Biovica: Expanding DiviTum’s Nordic market reach - Redeye

Biovica has established a partnership agreement with Axlab (A/S) to commercialize the DiviTum in the Nordics. Axlab is especially strong in Denmark and Norway, and the business includes Sweden, Finland and Iceland. Axlab is a top-5 brand in cancer screening and diagnostics in the Nordics. DiviTum will be supported by both Biovica and Axlab in Sweden, and we expect some of the larger centres to represent most of the commercial and clinical activity in Sweden and Denmark over the next 6-18 months. Axlab will showcase DiviTum in their channels and we also expect Axlab to expand the sales team with specialists working with DiviTum. We look forward to a more detailed DiviTum launch update during Biovica’s quarterly result (Q2 2023/24) on 28 November. We are especially interested in the process of approaching commercial DiviTum test volumes from the expanding US Direct Bill network.

Länk till analysen i sin helhet: https://www.redeye.se/research/958975/biovica-expanding-divitums-nordic-market-reach?utm_source=finwire&utm_medium=RSS